Imatinib mesylate should not be used in people who are allergic to the components of this drug, and should not be combined with CYP3A4 inducers such as rifampicin, and should be used with caution in people with hepatic impairment. Imatinib mesylate is a small molecule tyrosine kinase inhibitor, belongs to the anti-tumor targeting drugs, can be used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia, malignant gastrointestinal mesenchymal tumors. Imatinib mesylate should not be used in people who are allergic to the components of this drug; people with hepatic impairment should also be cautious of using this drug, because hepatic impairment may lead to increased exposure to the drug; secondly, co-administration with CYP3A4 inducers such as rifampicin, phenobarbital, and other drugs should be avoided, which will reduce the plasma concentration of imatinib and affect the therapeutic efficacy. Imatinib mesylate may cause adverse reactions such as water retention, edema, fatigue, malaise, fever, neutropenia, thrombocytopenia, anemia, and loss of appetite. At the same time, should follow the doctor’s instructions to regularly assess the blood picture, liver function, etc., if there is obvious discomfort also promptly reflect to the doctor. Please strictly follow the doctor’s instructions, do not self-medicate.